Related by context. All words. (Click for frequent words.) 67 nab paclitaxel 63 dose escalation clinical 63 REOLYSIN ® 63 randomized controlled Phase 63 Phase Ib clinical 62 Phase Ib II 62 subcutaneous SC 62 ongoing Phase 1b 62 phase Ib 62 docetaxel chemotherapy 61 #mg/m# [002] 61 fosbretabulin 61 phase IIa clinical 61 multicenter randomized controlled 61 PSMA ADC 61 Cloretazine ® 61 AVADO 60 Phase III VISTA 60 Cloretazine R 60 multicenter Phase 60 NSABP B 60 adecatumumab 60 phase Ib clinical 60 recurrent malignant glioma 60 #I TM# 60 Phase IIIb clinical 60 phase IIIb 60 assessing T DM1 60 multicenter Phase II 60 prospective multicenter 60 FOLFIRI chemotherapy 60 blinded randomized placebo controlled 59 docetaxel Taxotere ® 59 docetaxel Taxotere R 59 viral kinetic 59 doxorubicin cyclophosphamide 59 Ceplene/IL-2 59 ZACTIMA 59 dose escalation trial 59 Neuradiab TM 59 HCV RESPOND 2 59 ABCSG 59 daily Infergen 59 HuMax EGFr 59 VNP#M 59 Initiated Phase 59 registrational Phase 59 placebo controlled Phase 59 IMPACT DCM 59 Phase Ib study 59 evaluating tivozanib 59 EXPLORE Xa 59 treatment naive genotype 58 CLARITY study 58 AKT inhibitor 58 TAXUS ATLAS 58 multicentre randomized 58 CLORETAZINE TM VNP#M 58 Phase 1a clinical 58 alvespimycin 58 huN# DM1 58 viral kinetics 58 trastuzumab DM1 T DM1 58 PERSEUS 58 capecitabine Xeloda R 58 adecatumumab MT# 58 CALGB # [002] 58 BCIRG 58 HCV SPRINT 58 Initiate Phase 58 dose cohorts 58 Alocrest 58 dose cohort 58 MVax R 58 cisplatin gemcitabine 58 alfa 2a 58 EURIDIS 58 BRIM3 58 paclitaxel Taxol R 58 Xelox 58 BRIM2 58 HGS ETR1 57 IMGN# 57 Pivotal Phase III 57 maximally tolerated dose 57 neratinib 57 bendamustine 57 Randomized Phase 57 randomized Phase III 57 CBLC# 57 multicenter phase 57 Cloretazine R VNP#M 57 relapsed refractory multiple myeloma 57 Prostate AdenoCarcinoma Treatment 57 Phase Ia 57 phase IIb clinical 57 RECORD1 57 satraplatin Phase 57 mCi kg 57 Panzem R NCD 57 tolerability pharmacokinetics 57 Omacetaxine 57 galiximab 57 pharmacokinetic PK 57 mcg kg 57 PEG IFN 57 oral ridaforolimus 57 velafermin 57 HGS ETR2 57 dose escalation 57 dose escalation Phase 57 Doxil ® 57 5 fluorouracil leucovorin 57 bevirimat Study 57 SAR# [004] 57 multicenter Phase III 57 Tarceva TM 57 HGS# 57 mapatumumab 57 #mg QD [002] 57 bortezomib Velcade 57 doxorubicin docetaxel 57 paclitaxel carboplatin 57 pharmacokinetic PK study 57 mitomycin 57 CR# vcMMAE 57 randomized multicenter trial 57 double blinded randomized 56 GRNVAC1 56 axitinib 56 trastuzumab Herceptin R 56 imetelstat GRN#L 56 dose melphalan 56 depsipeptide 56 metastatic GIST 56 ascending dose 56 ELACYT 56 recurrent glioblastoma multiforme 56 Panzem NCD 56 CRLX# 56 telaprevir dosing 56 peg interferon 56 imetelstat 56 Phase III psoriasis 56 alpha 2a 56 Randomised 56 XL# SAR# 56 cilengitide 56 randomized controlled multicenter 56 dose escalation phase 56 fidaxomicin Phase 56 Phase 1b 56 relapsed MM 56 AAG geldanamycin analog 56 TLK# 56 preclinical efficacy 56 Proellex TM 56 pharmacodynamic PD 56 Maximum Tolerated Dose MTD 56 estramustine 56 Bezielle 56 Phase 2b kidney transplant 56 AIR CF2 56 Pemetrexed 56 phase IIa 56 Phase 1b trial 56 icatibant 56 FOLPI 56 bortezomib Velcade R 56 IIa trial 56 phase IIb study 56 ISTODAX ® 56 mg kg dose 56 multicenter randomized placebo controlled 56 CIMZIA TM 56 fallopian tube cancers 56 Pharmacodynamic 56 vinorelbine tartrate 56 oral rivaroxaban 56 Randomized controlled 56 pharmacokinetics PK 56 mg administered orally 56 Phase 1b clinical 56 GetGoal Phase III 56 Phase Ia Ib 56 ritonavir boosted 56 CA4P 56 ENDEAVOR III 55 nonrandomized 55 Active Ulcerative Colitis 55 Reolysin 55 CAMMS# 55 EOquin TM 55 YONDELIS 55 evaluating Prochymal 55 multicenter prospective 55 ExTRACT TIMI 55 Dose Ranging Study 55 CoFactor 55 HGS ETR1 mapatumumab 55 CLL8 55 randomized blinded 55 lorvotuzumab mertansine 55 Exherin TM 55 Combination REOLYSIN R 55 sorafenib Nexavar 55 bevacizumab Avastin ® 55 novel VDA molecule 55 telomerase inhibitor drug 55 Carotid Revascularization Endarterectomy vs. 55 PEGPH# 55 gemcitabine carboplatin 55 Taxotere R 55 Aeroquin 55 Phase 2a trial 55 TELCYTA 55 NEVO RES 55 pomalidomide 55 ara C 55 TMC# C# 55 BR.# 55 PHASE III 55 mg qd 55 prospective randomized controlled 55 papillary renal cell carcinoma 55 thorough QT 55 metastatic hormone refractory 55 Pharmacokinetic 55 ADVANCE PD 55 randomized discontinuation trial 55 Amrubicin 55 MAGE A3 ASCI 55 carboplatin paclitaxel 55 ganetespib 55 Xeloda ® 55 forodesine 55 melphalan prednisone 55 liposomal formulation 55 Phase #b/#a clinical 55 erlotinib Tarceva ® 55 Zevalin R Ibritumomab 55 Phase Ib 55 Solid Tumors 55 masked placebo controlled 55 refractory CLL 55 Phase 1a 55 eniluracil 55 Phase III Psoriasis 55 PEG SN# 55 ENESTnd 55 Intervention Effectiveness 55 placebo controlled Phase III 55 Phase III randomized controlled 55 lexidronam injection 55 biliary tract cancer 55 Chemophase 55 sorafenib Nexavar ® 55 CLARITY TIMI 55 PENNVAX B 55 ILLUMINATE 55 relapsed myeloma 54 randomized Phase IIb 54 indibulin 54 anastrazole 54 CHAMPION PCI 54 docetaxel Taxotere 54 Cotara 54 rapid virologic response 54 Phase IIb III 54 PRTX 54 Platinol ® cisplatin 54 paclitaxel poliglumex 54 Triapine R 54 oral deforolimus 54 Androxal TM 54 MGd 54 Phase 1b clinical trials 54 ORMD 54 fidaxomicin Phase 3 54 neoadjuvant 54 randomized Phase 2b 54 gemcitabine chemotherapy 54 subcutaneous PRO 54 phase IIb III 54 weekly intravenous infusions 54 epoetin alpha 54 IMPACT IMmunotherapy 54 mg/m2 cohort 54 Phase IIB 54 OMP #M# 54 elotuzumab 54 mg/m2 dose 54 metastatic HRPC 54 FOLFOX6 chemotherapy regimen 54 mg RDEA# 54 Randomized Phase II 54 resminostat 54 mg/m2/day 54 Phase 2b Study 54 NO# [002] 54 romidepsin 54 velafermin belinostat 54 double blinded placebo 54 azacitidine 54 PEGylated interferon beta 1a 54 unfractionated heparin UFH 54 optimal dosing 54 #mg/m# [001] 54 paclitaxel cisplatin 54 phase IIb 54 tolerated dose MTD 54 Randomized Evaluation 54 COU AA 54 Gemzar ® 54 Targretin capsules 54 antibody MAb 54 oral prodrug 54 initiate Phase 1b 54 BEZ# 54 omega interferon 54 teriflunomide 54 GOUT 54 TASKi3 54 initiated Phase Ib 54 IL# PE#QQR 54 Proxinium TM 54 ASSERT trial 54 RSD# oral 54 TTF Therapy 54 Dacogen injection 54 decitabine 54 chemotherapy docetaxel 54 HDAC Inhibitor 54 Randomized placebo controlled 54 ARIKACE 54 PXD# 54 peginterferon alpha 2a 54 pharmacokinetic parameters 54 PDX pralatrexate 54 randomized multicenter Phase III 54 dose dexamethasone 54 evaluating Xcytrin 54 tanespimycin 54 VELCADE melphalan 54 recurrent malignant gliomas 54 multicenter randomized 54 omacetaxine mepesuccinate 54 Randomized Double blind 54 amrubicin 54 Aplidin 54 ritonavir boosted danoprevir 54 GW# [003] 54 PFO migraine 54 DLTs 54 Long Lesion 54 eritoran 54 mertansine 54 IIa clinical 54 GLP toxicology studies 53 GAMMAGARD 53 lenalidomide Revlimid R 53 CUSTOM II 53 rALLy trial 53 Hsp# Inhibitor 53 darunavir ritonavir 53 dosing cohorts 53 farletuzumab 53 preclinical pharmacokinetic 53 CCX# B 53 Folfox 53 prospective observational studies 53 cetuximab Erbitux R 53 NCIC CTG 53 carboplatin 53 prospective randomized placebo 53 cediranib 53 Telintra 53 Phase #/#a 53 Phase 2b trial 53 registrational clinical 53 crizotinib PF # 53 Pegylated Liposomal Doxorubicin 53 sunitinib malate 53 PNT# 53 Phase III ADT 53 plus dexamethasone 53 telaprevir VX 53 EGFR HER2 53 safety tolerability pharmacokinetics 53 multicenter clinical 53 ACTIVE W 53 pertuzumab 53 Anthim 53 pegylated liposomal doxorubicin PLD 53 CALERIE 53 Phase IIIb 53 custirsen 53 maximal dose 53 multicenter randomized clinical 53 PCI ExTRACT TIMI 53 PRT# 53 randomized multicenter 53 lumiliximab 53 Phase #b/#a trial 53 demonstrated antitumor activity 53 pharmacodynamics PD 53 REOLYSIN R 53 refractory chronic lymphocytic 53 ZOLINZA 53 subcutaneous formulation 53 Xcellerated T Cells 53 XL# XL# XL# 53 multicenter randomized Phase 53 Traficet EN 53 HER2 positive metastatic breast 53 #nd EORTC NCI 53 CLL SLL 53 zonisamide SR 53 BrachySil 53 heavily pretreated 53 CA9 SCAN 53 Bayer HealthCare Onyx Pharmaceuticals 53 Forodesine HCl 53 dosage regimens 53 bepotastine besilate nasal spray 53 recurrent GBM 53 ug kg 53 PKC# 53 prospective randomized multicenter 53 Dyloject TM 53 TASKi2 53 Multicenter 53 Randomized Double Blind 53 evaluating Vectibix 53 placebo controlled clinical 53 Azedra 53 Vidaza ® 53 remission CR 53 5 Fluorouracil 53 lesinurad 53 Cloretazine 53 GSK# [001] 53 Pharmacokinetic parameters 53 confirmatory clinical 53 alefacept 53 BNC# 53 pegylated liposomal doxorubicin 53 Fludara 53 DCVax ® Brain 53 EmbraceAC 53 evaluating satraplatin 53 Vaxfectin TM 53 systemic RNAi therapeutic 53 relapsed APL 53 neurologic progression 53 GENASIS clinical 53 ancrod 53 Zybrestat 53 intravenous dosing 53 ENDEAVOR IV 53 huC# DM4 53 Taxotere ® 53 APPRAISE 53 riociguat 53 ISTODAX 53 levodopa induced dyskinesia 53 AIR CF1 53 mCRC patients 53 RE MODEL 53 STRIDE PD 53 SUCCEED trial 53 glycoprotein IIb IIIa inhibitor 53 multicentre randomized controlled 53 PI3K/Akt pathway inhibitor 53 Intervention Effectiveness CATIE 53 lapatinib Tykerb 53 RE LY 53 TELINTRA 53 PreCISe 53 oral picoplatin 53 DASISION 53 REVIVE Diabetes 53 hormone LHRH antagonist 53 Pivotal Phase 53 Phase IIA 53 monoclonal antibody conjugated 53 Aflibercept 52 Valortim ® 52 OncoVEX GM CSF 52 Phase Ib clinical trials 52 tinzaparin 52 Sapacitabine 52 afatinib 52 REOLYSIN 52 AMPAKINE CX# 52 Pharmacokinetics PK 52 Society CTOS 52 olaparib 52 paclitaxel Taxol ® 52 ToGA 52 Phase IIb clinical trials 52 DAPT 52 evaluable patients 52 PROSTVAC ® 52 lintuzumab 52 Matrix Phase 2b 52 taxane resistant 52 Triapine 52 Genasense ® oblimersen 52 NP2 Enkephalin 52 PREVENT IV 52 enzastaurin 52 Zemplar Capsules 52 rALLy 52 Dacogen decitabine 52 EMPHASIS HF trial 52 sodium thiosulfate STS 52 relapsed Hodgkin lymphoma 52 telomerase therapeutic 52 ACTEMRA TM 52 Gliadel Wafer 52 pegylated interferon alpha 2a 52 relapsing multiple sclerosis 52 teduglutide 52 TOLAMBA 52 histone deacetylase inhibitor 52 DIABECELL R 52 RE LY ® 52 acyclovir Lauriad R 52 NVA# 52 CIMZIA TM certolizumab pegol 52 recurrent metastatic 52 epirubicin cyclophosphamide 52 MEK inhibitor 52 limiting toxicity DLT 52 PRoFESS 52 Glufosfamide 52 Sandostatin LAR Depot 52 recurrent NSCLC 52 Kamada AAT 52 G#DT 52 Xanafide 52 IMA# 52 ABSORB clinical 52 TORISEL 52 CUSTOM III 52 trastuzumab DM1 52 TG MV 52 OXi# 52 temsirolimus 52 Phase 2b Clinical Trial 52 Val HeFT 52 IIb clinical trial 52 controlled multicenter Phase 52 blinded randomized 52 zalutumumab 52 patients evaluable 52 8mg/kg 52 ThermoDox 52 docetaxel 52 Neuradiab 52 PEG PAL 52 MEND CABG II 52 ORAL Sync 52 BrachySil TM 52 ON #.Na 52 Allovectin 7 ® 52 Randomized Clinical Trial 52 GRN#L 52 WX UK1 52 mRCC 52 R# #mg BID 52 RGB # 52 CCyR 52 MEND CABG 52 receptor tyrosine kinase inhibitor 52 TAXUS VI 52 Hormone Refractory Prostate Cancer 52 gemcitabine 52 Enzastaurin 52 Clinical Antipsychotic Trials 52 Sibutramine Cardiovascular Outcomes 52 Taxotere chemotherapy 52 REYATAZ r 52 Myocardial Infarction Study 52 randomized #:#:# 52 TAXUS Liberte Long 52 GMX# 52 AVERROES 52 ECASS 52 EFAPROXYN 52 metastatic castration resistant 52 BETAS 52 Romidepsin 52 gemcitabine cisplatin 52 cetrorelix pamoate 52 Meets Primary Endpoint 52 KNS # 52 pharmacodynamic effects 52 nilotinib 52 blind randomized controlled 52 VESTASYNC 52 recurrent glioma 52 refractory multiple myeloma 52 Cannabinor 52 label multicenter Phase 52 tipranavir r 52 adjuvant GIST 52 TRISENOX 52 pivotal bioequivalence 52 desvenlafaxine succinate 52 NCCTG 52 acute HAE attacks 52 genotypic resistance 52 PrevOnco 52 metastatic castrate resistant 51 FavId 51 STEALTH C 51 refractory prostate cancer 51 Tyrima 51 Sym# 51 DEB# 51 REMINYL ® 51 CYT# potent vascular disrupting 51 vismodegib 51 tocilizumab 51 Phase 2b study 51 Aptivus ® 51 KRN# 51 dose escalation study 51 prospective multicenter randomized 51 Phase IIB clinical 51 OvaRex MAb 51 chemotherapy cisplatin 51 INCB# [001] 51 daily subcutaneous injections 51 TACE 51 PF # [001] 51 trials RCTs 51 active comparator 51 Valortim 51 Protexia R 51 ABSORB trial 51 saline placebo 51 BoNTA 51 Omnitarg 51 Ereska 51 Phase 2a 51 IFN α 51 SPIRIT IV 51 low dose cytarabine 51 favorable pharmacokinetic profile 51 talabostat 51 ONTARGET 51 ofatumumab 51 Engerix B 51 investigational antiplatelet agent 51 PROSTVAC TM 51 budesonide foam 51 OncoGel 51 TMC# r 51 AVOREN 51 ZK EPO 51 catheter occlusion 51 randomized blinded placebo 51 Brentuximab Vedotin SGN 51 AACR NCI EORTC 51 Asentar 51 CYC# 51 multicenter placebo controlled 51 Multicenter Randomized 51 HuMax CD4 51 Resten MP 51 seliciclib 51 Phase #/#a trial 51 COR Diabetes 51 noninferiority 51 aflibercept VEGF Trap 51 CINTREDEKIN BESUDOTOX 51 Investigational Oral 51 Elotuzumab 51 Ophena 51 TriGrid 51 Platelet Inhibition 51 obatoclax 51 TAXUS V 51 Severe Sepsis 51 Deforolimus 51 dosing regimens 51 pharmacodynamic markers 51 anticancer compound 51 ALN TTR# 51 orally inhaled migraine 51 bortezomib Velcade ® 51 mycophenolate mofetil 51 Selective Internal 51 Vectibix monotherapy 51 Pralatrexate 51 Bortezomib 51 DSMB recommended 51 BOLDER II 51 Vicinium TM 51 APOPTONE 51 multicentre 51 ALN VSP Phase 51 ENMD # 51 ALN HPN 51 Multiple Ascending Dose 51 Preclinical studies 51 ThermoDox R 51 Recurrent Glioblastoma 51 LEP ETU 51 Novo TTF 51 subcutaneous methylnaltrexone 51 M Vax 51 NSABP 51 ZYBRESTAT fosbretabulin 51 AQ4N 51 designated HVTN 51 investigational protease inhibitor 51 AeroLEF TM 51 Mitoxantrone 51 Subgroup analysis 51 AP# [003] 51 weekly subcutaneous injections 51 Ophena TM 51 relapsed MCL 51 Imprime PGG 51 noninferior 51 Golimumab 51 balsalazide tablet 51 interferon beta 1b 51 LymphoStat B Phase 51 Phase Ib Clinical Trial 51 preclinically 51 Phase 2b clinical 51 ruxolitinib 51 davunetide intranasal AL 51 multicenter multinational 51 pentostatin 51 midstage clinical 51 trastuzumab Herceptin ® 51 COMFORT II 51 TRANSFORMS 51 temozolomide 51 prostate cancer HRPC 51 HCD# [002] 51 IFN alfa 51 landmark ATHENA 51 evaluating MGCD# [002] 51 DAVANAT 51 MT# MEDI 51 ixabepilone 51 Alfimeprase 51 blinded placebo controlled 51 IMPACT DCM clinical 51 zanolimumab 51 Metastatic Melanoma 51 hENT1 51 docetaxel prednisone 51 Phase IIa clinical 51 Sorafenib HCC Assessment 51 Phase IIIb study 51 PANVAC VF 51 metastatic malignant 51 antiretroviral naïve 51 quadrivalent HPV vaccine 50 celgosivir 50 HspE7 50 azilsartan medoxomil 50 refractory cutaneous T 50 oral antiviral 50 thalidomide Thalomid 50 Initiates Phase II 50 Phase Ib IIa 50 Darinaparsin 50 pharmacodynamic 50 Jevtana 50 bevacizumab 50 Vitaxin 50 biochemical relapse 50 EINSTEIN DVT 50 Phase #b/#a 50 AEG# 50 prospective nonrandomized 50 phase III ACCLAIM 50 Pre RELAX AHF 50 OvaRex R 50 CRMD# 50 sarcoma melanoma 50 intravenous picoplatin 50 combination REOLYSIN 50 randomized controlled clinical trials 50 cyclophosphamide FC 50 RE SURGE 50 interferon gamma 1b 50 Pivotal Trial 50 Phase 2a clinical 50 TAXUS IV 50 chlorambucil 50 Bosutinib 50 Phase III multicenter 50 hA# 50 antitumor activity 50 thymalfasin 50 Adenoma Prevention 50 Pyridorin 50 intravesical infusion therapy 50 tipifarnib 50 RAV# 50 Initiates Phase 2b 50 trastuzumab emtansine T DM1 50 CALGB 50 Anturol TM 50 abacavir lamivudine 50 BrachySil ™ 50 Delcath Phase III 50 Onconase 50 orally administered inhibitor 50 clinical trials Multikine 50 CCX# 50 NEUVENGE 50 PrevOnco ™ 50 vorinostat 50 CYT# 50 Parathyroid Hormone 50 MVA MUC1 IL2 50 EVEREST II 50 CEQ# 50 relapsed multiple myeloma 50 nonclinical studies 50 Pharmacokinetic PK 50 rituximab 50 dependent kinase inhibitor 50 PNP inhibitor 50 iniparib 50 EchoCRT 50 EGS# 50 UPLYSO 50 recurrent metastatic ovarian cancer 50 dose cytarabine 50 Neulasta ® 50 refractory AML 50 Arranon 50 Augment Injectable 50 TransVax tm 50 palifosfamide 50 LUMINATE 50 Hedgehog Pathway Inhibitor 50 multicentre prospective 50 DermaVir Patch 50 adjuvant cisplatin 50 SPIRIT FIRST 50 pemetrexed Alimta 50 Aryplase 50 CRu 50 Ceflatonin 50 Relapsing Multiple Sclerosis 50 glufosfamide 50 placebo controlled randomized 50 Intravitreal 50 bortezomib 50 CR CRu 50 EDEMA3 trial 50 sorafenib tablets 50 Acute Myocardial Infarction 50 everolimus eluting stents 50 Tectin TM 50 lintuzumab SGN 50 aurora kinase inhibitor 50 TACI Ig 50 multicenter randomized double 50 R#/MEM # 50 limiting toxicity 50 preclinical pharmacology 50 rALLy clinical trial 50 radiolabeled TM# 50 #mg ATC 50 phase IIb trial 50 Refractory Angina 50 non nucleoside HCV 50 prospectively defined 50 IMC A# 50 pediatric pontine glioma 50 FOLOTYN ® 50 LE DT 50 Phase III ThermoDox 50 CCR5 mAb 50 Teriflunomide 50 INSPIRE Trial Phase III 50 randomized Phase 50 EOquin 50 GVAX R 50 dose regimens 50 follicular NHL 50 ALN TTR 50 AEOL # 50 uridine triacetate 50 GAP #B# 50 TNFerade 50 relapsing remitting MS RRMS 50 SparVax TM 50 IMP# 50 combination REOLYSIN R 50 PROTECT AF 50 agonistic human 50 PSN# [002] 50 locoregional disease 50 Phase III placebo controlled 50 BLP# Liposome Vaccine 50 Velcade bortezomib 50 analgesic efficacy 50 RH1 50 Annamycin 50 LymphoStat B TM 50 tramiprosate Alzhemed TM 50 Lovaxin C 50 metaglidasen 50 Phase IIa trials 50 Telcyta 50 Mylotarg 50 Completes Patient Enrollment 50 prospectively randomized 50 AIM HIGH 50 SPRYCEL ® 50 Phase III TRIST 49 clinical pharmacology studies 49 Onyx Pharmaceuticals Announces 49 refractory acute myeloid 49 CD# CEA 49 doublet chemotherapy 49 Medidur TM FA 49 OvaRex ® MAb 49 registrational 49 MGCD# [001] 49 Temsirolimus 49 Left Ventricular Dysfunction 49 IgG1 monoclonal antibody 49 ganaxolone 49 Safinamide 49 dacetuzumab 49 midstage trials 49 CHARM Added 49 ENDEAVOR II 49 ADAGIO study 49 formal pharmacokinetic PK 49 Ontak 49 placebo controlled dose escalation 49 Clolar ® 49 IIa clinical trials 49 ascending dose study 49 entinostat 49 locoregional 49 Targretin 49 ularitide 49 Albuferon Phase 49 evaluable 49 placebo controlled studies 49 ENGAGE AF TIMI 49 aflibercept 49 stage IIIb IV 49 IIa clinical trial 49 Clinical Trial Results 49 Azedra TM 49 ADMIRE HF 49 APEX PD 49 INCB# [003] 49 Phase 2b randomized 49 picoplatin 49 OBPM 49 MIRCERA 49 Platinol 49 PLK1 SNALP 49 phase III isavuconazole 49 XL# XL# 49 ThermoDox ® clinical 49 confirmatory Phase 49 Phase #/#a clinical 49 ICA # 49 ONCONASE 49 evaluating mipomersen 49 number NCT# ClinicalTrials.gov 49 PEARL SC 49 Dose escalation 49 Tesetaxel 49 prostate cancer mCRPC 49 initiated Phase 1b 49 MyVax personalized immunotherapy 49 Phase IIb randomized 49 tiuxetan 49 prostate cancer AIPC 49 NEUMUNE 49 Phase Ib IIa clinical 49 previously untreated follicular 49 including eniluracil ADH 49 Phase 2b monotherapy 49 OvaRex 49 Provecta 49 Trial Evaluating